Cantor Fitzgerald Downgrades aTyr Pharma (ATYR) to Neutral

Cantor Fitzgerald analyst Prakhar Agrawal downgraded aTyr Pharma (NASDAQ: ATYR) from Overweight to Neutral.

The analyst comments "aTyr announced that the Phase 3 pulmonary sarcoidosis (PS) trial for efzofitimod (Efzo) missed the primary endpoint of change in mean steroid dose from baseline at week 48. aTyr plans to engage with the FDA to determine the path forward for Efzo in PS. We downgrade to Neutral as we don’t have much confidence in the path forward for Efzo in pulmonary sarcoidosis, as: 1) secondary endpoints are all nominal (many endpoints still have nominal p-values > 0.05). 2) for the key secondaries, there is only 10-15% improvement over placebo – for e.g., on the key secondary endpoint of complete steroid withdrawal -- 53% of high dose arm patients were steroid-free vs. 40% on placebo."

For an analyst ratings summary and ratings history on aTyr Pharma click here. For more ratings news on aTyr Pharma click here.

Shares of aTyr Pharma closed at $6.03 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy